Skip to main content
CRS 2025 Annual Meeting & Exposition Main banner
Rate Poster

Nanomedicine and Nanoscale Delivery (Focus Group - NND)

(346) Nano-in-micro particles for the pulmonary delivery of remdesivir

Introduction: Remdesivir (RDV) emerged as a potential therapeutic option to treat COVID-19 in patients with comorbidities [1,2]. Due to its low oral bioavailability, RDV must be administered intravenously (2h infusion), and the rapid metabolism during systemic circulation may further limit its therapeutic efficacy in the lungs, since the active metabolite is unable to penetrate cell membranes [3]. Here we developed an inhalable formulation of nanoparticles (NPs) incorporated into microparticles (MPs) for pulmonary delivery of RDV.

Learning Objectives:

  • Nanoencapsulation of remdesivir resulted in stable and high load nanoparticles;
  • The nano-in-microparticles present adequate size to deliver remdesivir to the lungs;
  • The formulation developed is promising to incorporate other drugs to treat pulmonary diseases.